Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

257.01 -0.82 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Biogen Stock Pops Despite New FDA Limits On Alzheimer's Drug Use
Biogen stock rose Thursday after the Food and Drug Administration signed off on narrower recommendations for Alzheimer's drug Aduhelm. 
Via Investor's Business Daily
Exposures Product Safety
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Biogen Inc. (NASDAQ:BIIB) shares are lower after the compa... 
Via Benzinga
Exposures Product Safety
Oracle And CarMax Lead The SPY Higher Wednesday
U.S. indices were trading higher Wednesday after the 10-year treasury yield fell to its lowest level since February at 1.3%. The ... 
Via Benzinga
Is Eli Lilly a Better Alzheimer's Stock Than Biogen?
An unusually lenient FDA is a knife that cuts both ways for Biogen. 
Via The Motley Fool
Exposures Product Safety
Friday Trades And June Summary
Trading performance has been very good year to date. I had thought I needed to tighten my belt but I made it by just fine. 
Via Talk Markets
What 17 Analyst Ratings Have To Say About Biogen
Analysts have provided the following ratings for Biogen (NASDAQ: 
Via Benzinga
Unusual Options Activity Insight: Biogen
Biogen (NASDAQ:BIIB) shares experienced unusual options activity on Tuesday. The stock price moved down to $343.7 following the option alert. Sentiment: NEUTRAL Option Type:... 
Via Benzinga
Lundbeck Out Licenses Flopped Alzheimer's Drug In Wake Of Biogen's Controversial Success With Aducanumab
Privately-held Denovo Biopharma LLC has in-licensed global rights for idalopirdine from H. Lundbeck A/S (OTC: HLUYY) for all indications. The deal... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
Analyzing Biogen's Unusual Options Activity
On Wednesday, shares of Biogen (NASDAQ:BIIB) saw unusual options activity. After the option alert, the stock price moved up to $348.49. Sentiment: BEARISH Option Type: TRADE... 
Via Benzinga
How Biogen Made an Enemy of 1 of the Biggest Supporters of Its Alzheimer's Disease Drug
A nonprofit group doesn't like a recent move by Biogen. 
Via The Motley Fool
Exposures Product Safety
3 Better Alzheimer’s Drug Stocks to Buy Instead of Biogen
These drug stocks are in competition with Biogen for an Alzheimer's treatment, and can break out in a similar fashion offering better value. 
Via InvestorPlace
Could Biogen's Big Win With Aduhelm Become a Big Liability?
It's looking more and more likely. 
Via The Motley Fool
How Bad Is Biogen's Latest Bad News?
The drugmaker has had one big clinical setback and another less serious disappointment in recent weeks. 
Via The Motley Fool
Facebook And Nvidia Lead The QQQ Higher Monday
The Nasdaq was trading sharply higher throughout Monday’s session amid a rebound in growth and tech names. The Inve... 
Via Benzinga
Earnings Roundup: Adobe, Kroger, The Honest Company, and More
Discussing the latest news and how to move from growth-focused investing to a value approach. 
Via The Motley Fool
Biogen's Costly Alzheimer's Treatment May Face Restricted Medicare Access: WSJ
The recent approval of Biogen Inc's (NASDAQ: BIIB) high-price Alzheimer's drug is raising questions about who will have access to the $56,000/year... 
Via Benzinga
Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 Trials
Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company’s corporate outlook, Green... 
Via Benzinga
New Alzheimer’s Treatment Is A Huge Catalyst for Biogen
BIIB stock was boosted when its Alzheimer's drug was approved. The company's strong financials can sustain the stock's growth. 
Via InvestorPlace
10 Biggest Price Target Changes For Monday
Barclays raised the price target for Accenture plc (NYSE: 
Via Benzinga
The Upside for Biogen Is Absolutely Wild
It's hard to believe how large Biogen's market opportunity is, now that the FDA has approved its Alzheimer's drug. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis Product Safety
Why Biogen's FDA Approval Is Shocking
Many doctors don't like the drug, and the trial data was underwhelming. Nonetheless, Biogen's Alzheimer's drug was approved-- and the market opportunity is huge. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis Product Safety
Is It Too Late to Buy Cassava Sciences Stock?
Just because the stock has had a massive run doesn't mean its biggest gains are behind it. 
Via The Motley Fool
Alzheimer's Biotech Acumen Pharmaceuticals Prices $125M IPO Soon After Biogen's Aduhelm Approval
Acumen Pharmaceuticals Inc has set the terms for its IPO to raise around $125 million to take ACU193, an antibody against amyloid-beta oligomers, to the end of phase 2 in... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Stock Market Rally Revs To New Highs; Nike, Google, FedEx, Eli Lilly, Amazon In Focus: Weekly Review
The Nasdaq and S&P 500 hit highs as the stock market rally perked up, helped by a Biden infrastructure deal. Nike soared on earnings. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Crazy Thursday
Today the US stock market went ballistic probably because of a higher joblessness level than expected. 
Via Talk Markets
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. 
Via InvestorPlace
Lilly Stock Hits Record High On Key Alzheimer's Win, Looking To Follow Biogen
Eli Lilly's experimental Alzheimer's treatment snagged a key FDA designation on Thursday. LLY stock surged to a record high. 
Via Investor's Business Daily
Exposures Product Safety
Why Eli Lilly Stock Is Soaring Today
The company's promising Alzheimer's disease drug won FDA Breakthrough Therapy designation. 
Via The Motley Fool
Exposures Product Safety
Eli Lilly Jumps On Expedited Plans For Alzheimer's Drug, Biogen Falls
Eli Lilly announced that the Food and Drug Administration granted Breakthrough Therapy designation for donanemab, its investigational antibody therapy for Alzheimer's disease. 
Via Talk Markets
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.